NEW YORK – Australian diagnostics firm Sienna Cancer Diagnostics said on Thursday it appointed Immuno Diagnostic its exclusive distributor in Finland.
As part of the agreement, Immuno Diagnostic, based in Hämeenlinna, Finland, will have the right to sell Sienna's CE-marked hTERT (human telomerase reverse transcriptase) test to Finnish pathology labs to help diagnose bladder cancer. About 1,200 new cases of the disease are diagnosed in Finland each year, Sienna noted.
It is Sienna's fourth distribution appointment covering Europe, and in a statement Minesh Lalla, the firm's business development manager, said that in the coming year, Sienna will continue its expansion into region with Germany, France, Italy, Greece, and Spain as high priority targets.
Sienna will provide sales, marketing, and technical support training to Immuno Diagnostics staff, as well as establish a reference lab to get the test adopted. Financial and other terms of the agreement were not disclosed.
In December, Sienna announced it raised A$1.7 million.